A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.
Clin Cancer ResSep 1, 2026
Hui K Gan, Lawrence Cher, Po-Ling Inglis et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I multicenter study evaluated the safety and biodistribution of ifabotuzumab, an EphA3-targeted antibody, in 12 adults with recurrent glioblastoma. Patients received either 3.5 or 5.25 mg/kg of ifabotuzumab, with PET scans using 89Zr-ifabotuzumab showing specific tumor uptake. No objective responses were observed, but one patient experienced prolonged stable disease.
Key findings
- No objective responses were observed, but one patient had prolonged stable disease.
- Two patients exhibited changes in peritumor edema, suggesting tumor vasculature modulation.
- 89Zr-ifabotuzumab scans demonstrated specific tumor uptake in all patients, aligning with MRI and PET imaging.
Why it matters
Understanding the safety and biodistribution of targeted therapies like ifabotuzumab is crucial for developing effective treatments for recurrent glioblastoma, a challenging malignancy with limited options.